Poor
Not Aligned
Patient Risk:
Moderate
Summary
Core mechanism and identity claims align with the provided label excerpts, but multiple safety-related claims (drowsiness/fatigue incidence, sedation-related interactions, and proposed drowsiness mechanism/neurotransmitter link) are unsupported by the provided prescribing information sections, creating material labeling non-adherence.
Category Scores
Accurate Statements
Lipitor is also known as atorvastatin.
11 DESCRIPTION identifies LIPITOR as atorvastatin.
Lipitor is a statin medication that belongs to the HMG-CoA reductase inhibitor class.
11 DESCRIPTION and 12.1 describe atorvastatin as an HMG-CoA reductase inhibitor.
Lipitor works by blocking the production of cholesterol in the liver.
12.1 describes inhibition of cholesterol synthesis (including hepatic cholesterol synthesis).
Lipitor reduces low-density lipoprotein (LDL) cholesterol levels in the blood.
12.1 states LIPITOR lowers plasma cholesterol/lipoprotein levels and reduces LDL-C.
Unsupported Statements
Drowsiness is a relatively common side effect of Lipitor.
The provided label excerpts do not mention drowsiness as an adverse reaction.
Approximately 10% of patients taking Lipitor experience drowsiness or fatigue as a side effect.
No incidence/percentage for drowsiness or fatigue is provided in the supplied label excerpts.
Lipitor can interact with other medications such as sedatives or antidepressants, which can increase the risk of drowsiness.
The provided drug interaction excerpt (7) discusses myopathy risk with specific agents and does not describe sedative/antidepressant interactions or a drowsiness risk.
The mechanism of Lipitor causing drowsiness is not fully understood.
No label discussion of drowsiness (or its mechanism) appears in the supplied excerpts.
Lipitor may be related to changes in neurotransmitter levels in the brain, such as serotonin and dopamine, which play a role in regulating sleep and wakefulness.
No label discussion of neurotransmitter (serotonin/dopamine) changes or sleep/wake regulation in relation to Lipitor is included in the supplied excerpts.
Contradictions
Important Omissions
For the specific safety claim about sedation/drowsiness risk (including incidence), the labeling excerpt set does not provide any supported counterpart (e.g., a confirmed adverse reaction list item for drowsiness or fatigue with incidence).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported statements introduce unverified safety effects (drowsiness/fatigue) and interaction implications (sedatives/antidepressants increasing drowsiness), which could mislead safety expectations despite no direct contradictions being identified in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple adverse reaction and interaction claims about drowsiness/fatigue are not supported by the provided prescribing information excerpts.
Suggested Improvement
Remove or revise all drowsiness/fatigue-related claims (including incidence, sedative/antidepressant interaction framing, and neurotransmitter mechanism) unless supported by the prescribing information; retain only label-supported mechanism/identity statements found in the provided excerpts.